2024-10-04
ENA first public
ERC000011
ENA-CHECKLIST
Laboratory of Molecular Medicine and Genomics
INSDC center name
public
INSDC status
ERS18400091
SRA accession
E-MTAB-13884:Sample 9
Submitter Id
ArrayExpress
broker name
MCF-7
cell_line
breast invasive ductal carcinoma cell
cell_type
not collected
collection date
human
common name
Protocols: BRPF1 knock-down was performed plating approximately 3000 cells in each well of a 96-well plate in standard growth medium. After overnight incubation, transient transfection was assessed by using Lipofectamine RNAiMax (13778-150, Invitrogen) diluted in Optimem medium, according to the manufacturer's instructions. 0.5 pM/well of two validated BRPF1 siRNAs (s17208, s17210) or scramble Silencer Select Negative Control (SiSel_NC1) (Ambion, Thermo Fisher Scientific) were added in quadrupled/sixfold each one and incubated for 72h at 37 °C/5% CO2. Total RNA was extracted from all cell lines aafter siRNA-transfection using TRIzol reagent (Life Technologies, Carlsbad, CA), according to the manufacturer’s instructions  indexed libraries were prepared starting from 1 total RNA according to Illumina Stranded Total RNA prep Ligation with Ribo-Zero Plus kit (Illumina Inc., San Diego, CA, USA).
description
breast cancer
disease
not collected
geographic location (country and/or sea)
not applicable
isolate
Homo sapiens
organism
Homo sapiens
organism
breast
organism part
1
replicate
Homo sapiens
scientific_name
Sample 9
title